{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:04:53Z","timestamp":1759334693067,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.jaad.2005.01.104","type":"journal-article","created":{"date-parts":[[2005,4,11]],"date-time":"2005-04-11T16:05:33Z","timestamp":1113235533000},"page":"1100-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Thalidomide in mycosis fungoides"],"prefix":"10.1016","volume":"52","author":[{"given":"Lori","family":"Brightman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-France","family":"Demierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.01.104_bib1","first-page":"177","article-title":"Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations","volume":"46","author":"Zwingenberger","year":"1995","journal-title":"J Inflamm"},{"key":"10.1016\/j.jaad.2005.01.104_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1523-1747.2003.12565.x","article-title":"Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells","volume":"121","author":"Deng","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2005.01.104_bib3","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.104_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/1042819031000079096","article-title":"Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease","volume":"44","author":"Flowers","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2005.01.104_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/clim.2001.5173","article-title":"Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement","volume":"102","author":"Oliver","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2005.01.104_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures","volume":"99","author":"McHugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2005.01.104_bib7","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2005.01.104_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.01.104_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2005.01.104_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2005.01.104_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2003.07.006","article-title":"Treatment of cutaneous sarcoidosis with thalidomide","volume":"50","author":"Nguyen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.01.104_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":"Low-dose thalidomide treatment for advanced hepatocellular carcinoma","volume":"65","author":"Hsu","year":"2003","journal-title":"Oncology"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205004378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205004378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:37:40Z","timestamp":1759268260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962205004378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0190962205004378"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.104","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide in mycosis fungoides","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}